GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Sloan Ratio %

Paion Ag (Paion Ag) Sloan Ratio % : 0.00% (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Paion Ag's Sloan Ratio for the quarter that ended in Jun. 2023 was 0.00%.

As of Jun. 2023, Paion Ag has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Paion Ag Sloan Ratio % Historical Data

The historical data trend for Paion Ag's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Sloan Ratio % Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.87 -16.68 4.72 50.56 -12.92

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.57 53.31 4.06 -12.91 -

Competitive Comparison of Paion Ag's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion Ag's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Paion Ag's Sloan Ratio % falls into.



Paion Ag Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Paion Ag's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(-0.613-6.293
--1.68)/40.442
=-12.92%

Paion Ag's Sloan Ratio for the quarter that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2023 )
=(-21.27--12.77
--1.012)/34.926
=-21.44%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Paion Ag's Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was -10.845 (Dec. 2022 ) + -10.425 (Jun. 2023 ) = $-21.27 Mil.
Paion Ag's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was -6.396 (Dec. 2022 ) + -6.374 (Jun. 2023 ) = $-12.77 Mil.
Paion Ag's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 was -1.012 (Dec. 2022 ) + 0 (Jun. 2023 ) = $-1.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag  (OTCPK:PAIOF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2023, Paion Ag has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Paion Ag Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Paion Ag's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.